Old Web
English
Sign In
Acemap
>
authorDetail
>
Mark Wildgust
Mark Wildgust
Bristol-Myers Squibb
Myeloid leukemia
Imatinib
Dasatinib
Medicine
Oncology
3
Papers
353
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
3-year follow-up from a randomized phase 3 trial (DASISION) Early response with dasatinib or imatinib in chronic myeloid leukemia:
2014
Andreas Hochhaus
Dong-Wook Kim
M. Brigid Bradley-Garelik
Hesham Mohamed
Mark Wildgust
Charles Chuah
Carolina Pavlovsky
Jiri Mayer
Jorge Cortes
Hagop M. Kantarjian
Giuseppe Saglio
Juan Luis Steegmann
Neil P. Shah
Show All
Source
Cite
Save
Citations (1)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
2014
Blood
Elias Joseph Jabbour
Hagop M. Kantarjian
Giuseppe Saglio
Juan Luis Steegmann
Neil P. Shah
Concepción Boqué
Charles Chuah
Carolina Pavlovsky
Jiri Mayer
Jorge E. Cortes
Michele Baccarani
Dong-Wook Kim
M. Brigid Bradley-Garelik
Hesham Mohamed
Mark Wildgust
Andreas Hochhaus
Show All
Source
Cite
Save
Citations (318)
Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data
2012
Blood
Giuseppe Saglio
Hagop M. Kantarjian
Neil P. Shah
Elias Jabbour
Alfonso Quintás-Cardama
Juan Luis Steegmann
Concepción Boqué
Charles Chuah
Carolina Pavlovsky
Jiri Mayer
Jon Ukropec
Mark Wildgust
Andreas Hochhaus
Show All
Source
Cite
Save
Citations (34)
1